Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “FLT3-Mutated High-Risk Myelodysplastic Syndrome”

8 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 8 of 8 results

Testing effectiveness (Phase 2)WithdrawnNCT02829840
What this trial is testing

Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)

Who this might be right for
LeukemiaFLT3-Mutated Acute Myeloid LeukemiaFLT3-Mutated High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT02530476
What this trial is testing

Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia

Who this might be right for
LeukemiaAcute Myeloid Leukemia
M.D. Anderson Cancer Center 17
Testing effectiveness (Phase 2)Looking for participantsNCT04140487
What this trial is testing

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Who this might be right for
Recurrent Acute Myeloid LeukemiaRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic/Myeloproliferative Neoplasm+3 more
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00045942
What this trial is testing

PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Novartis Pharmaceuticals 144
Testing effectiveness (Phase 2)Looking for participantsNCT05010122
What this trial is testing

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Acute Myeloid Leukemia+1 more
M.D. Anderson Cancer Center 42
Testing effectiveness (Phase 2)Temporarily pausedNCT04278768
What this trial is testing

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Who this might be right for
Acute Myelogenous LeukemiaMyelodysplastic Syndrome
Curis, Inc. 366
Testing effectiveness (Phase 2)Study completedNCT02196857
What this trial is testing

Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 16
Testing effectiveness (Phase 2)Study completedNCT01760655
What this trial is testing

Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD MutationAcute Myeloid Leukemia With Gene MutationsAcute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM+18 more
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 62
97